Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Chemocentryx Inc. on Thursday, setting a price target of $84, which is approximately 73.81% above the present share price of $48.33.
Schwartz expects Chemocentryx Inc. to post earnings per share (EPS) of -$0.43 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in ChemoCentryx (NASDAQ:CCXI), with an average price target of $92.83.
The analysts price targets range from a high of $120 to a low of $79.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $4.23 million and a net profit of -$29.58 million. The company's market cap is $3.37 billion.
According to TipRanks.com, Leerink Partners analyst Joseph Schwartz is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.8% and a 49.43% success rate.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.